GoldenGolden
Cue Health

Cue Health

Cue Health is a San Diego-based medical device company working to track health information at the molecular level.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

June 12, 2020
Cue Health says it has received an Emergency Use Authorization (EUA) for its rapid, point-of-care COVID-19 test.
June 10, 2020
Cue Health raises a $100,000,000 series C round from Decheng Capital.
2020
Cue Health raises a $13,000,000 grant from Biomedical Advanced Research and Development Authority.
2020
Cue Health raises a $102,600,000 series C round from ACME Capital, Decheng Capital, Foresite Capital, Johnson & Johnson Innovation – JJDC and Madrone Capital Partners.
2018
Cue Health raises a $45,000,000 series B round from BABEL Ventures, Cove Investments, Dentsu Ventures, Johnson & Johnson, Pritzker Group Venture Capital, Rohan Oza, Section 32, Sherpa Capital, Synergy Ventures and Troy Capital Partners.
2017
Cue Health raises a $15,500,000 series B round from Flat World Partners, MaC Venture Capital, Rohan Oza and Sherpa Capital.
2014
Cue Health raises a $7,500,000 series A round from Immortalana, Jim Messina, Leonardo DiCaprio, Marc Benioff and Sherpa Capital.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Conor Hale
March 8, 2021
FierceBiotech
One year into the pandemic, the FDA has authorized its first molecular COVID-19 diagnostic that can be performed completely at home and purchased without a prescription.
November 19, 2020
WebWire
The U.S. Department of Health and Human Services (HHS) has launched a pilot program with five states to use portable, cartridge-based COVID-19 molecular test kits that provide rapid results. The pilot program will assess how to best integrate diagnostic technology developed by Cue Health, Inc., into strategies for disease surveillance and infection control in institutions such as nursing homes. Used successfully as the primary molecular point-of-care (POC) test to control the spread of CO...
Darrell Etherington
June 12, 2020
TechCrunch
Fresh off a $100 million Series C funding round, molecular diagnostics startup Cue Health has more good news - it has received an Emergency Use Authorization (EUA) for its rapid, point-of-care COVID-19 test. The company got a $13 million grant from BARDA in March to help it scale its development and deployment of rapid diagnostics, [...]
Darrell Etherington
March 31, 2020
TechCrunch
Biotech startup Cue Health has secured a $13 million contract from the U.S. Department of Health and Human Service' Biomedical Research and Development Authority (BARDA), which will be used to speed the development and testing of a handheld molecular test that can detect the presence of the SARS-CoV-2 novel coronavirus that causes COVID-19. Cue, which [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.